Intravenous thrombolysis remains the gold standard in the management of acute ischemic stroke if the patient presents within the window period. Endovascular thrombectomy is another line of therapy in selected cases. Nonetheless, one of the most devastating complications of IV thrombolysis is intracranial hemorrhage (ICH); in such cases, the previous history of ICH is considered a potential contraindication to thrombolysis. Evidence regarding the safety of thrombolysis administration in patients with a previous history of ICH is scarce. We encountered a patient with acute ischemic stroke with a past history of hypertensive ICH. A 59-year-old female, presented with complete right-sided body weakness, global aphasia and gaze preference. A computed tomography (CT) brain perfusion scan revealed a mismatch suggestive of left middle cerebral artery (MCA) ischemic stroke. The patient received intravenous thrombolysis and showed significant clinical improvement with no subsequent complications or ICH. In reporting this case, we aim to provide evidence supporting the safety of thrombolytic therapy in selected cases with a previous history of ICH when no alternative line of management is available.
References
[1]
Marler, J. (1996) Tissue Plasminogen Activator for Acute Ischemic Stroke. New England Journal of Medicine, 334, 1405-1406.
https://doi.org/10.1056/NEJM199605233342114
[2]
Sacco, R., Kasner, S., Broderick, J. and Caplan, L. (2013) An Updated Definition of Stroke for the 21st Century. Stroke, 44, 2064-2089.
https://doi.org/10.1161/STR.0b013e318296aeca
[3]
Diedler, J., Ahmed, N., Sykora, M., Uyttenboogaart, M., Overgaard, K., Luijckx, G., Soinne, L., Ford, G., Lees, K., Wahlgren, N. and Ringleb, P. (2010) Safety of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients Receiving Antiplatelet Therapy at Stroke Onset. Stroke, 41, 288-294.
https://doi.org/10.1161/STROKEAHA.109.559724
[4]
Doberstein, C., Torabi, R., Yan, S., Mctaggart, R., Doberstein, C. and Jayaraman, M. (2017) Current Strategies in the Surgical Management of Ischemic Stroke. Rhode Island Medical Journal, 100, 25.
[5]
French, B., Boddepalli, R. and Govindarajan, R. (2016) Acute Ischemic Stroke: Current Status and Future Directions. Missouri Medicine, 113, 480-486.
[6]
Zhao, G., Wang, Z., Lin, F., Cui, Y. and Xu, S. (2019) The Safety and Efficacy of tPA Intravenous Thrombolysis for Treating Acute Ischemic Stroke Patients with a History of Cerebral Hemorrhage. Brazilian Journal of Medical and Biological Research, 52, e7739. https://doi.org/10.1590/1414-431x20187739
[7]
Lee, S., Kim, B., Han, M., Park, T., Lee, K., Lee, B., Yu, K., Oh, M., Cha, J., Kim, D., Nah, H., Lee, J., Lee, S., Ko, Y., Kim, J., Park, J., Kang, K., Cho, Y., Hong, K., Choi, J., Kim, J., Choi, K., Kim, D., Ryu, W., Kim, W., Shin, D., Yeo, M., Lee, J., Lee, J., Gorelick, P. and Bae, H. (2020) Should We Exclude Acute Stroke Patients with Previous Intracerebral Hemorrhage from Receiving Intravenous Thrombolysis? International Journal of Stroke, 7, 783-790.
[8]
Clark, W., Wissman, S., Albers, G., Jhamandas, J., Madden, K. and Hamilton, S. (1999) Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours after Symptom Onset. JAMA, 282, 2019.
https://doi.org/10.1001/jama.282.21.2019
[9]
David, C., Krieger, D., Villar-Cordova, C., Kasner, S., Morgenstern, L., Bratina, P., Yatsu, F. and Grotta, J. (1998) Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke. Stroke, 29, 18-22. https://doi.org/10.1161/01.STR.29.1.18
[10]
Zand, R., Tsivgoulis, G., Sadighi, A., Singh, M., McCormack, M., Shahjouei, S., Goyal, N., Noorbakhsh-Sabet, N., Alexandrov, A. and Alexandrov, A. (2018) Safety of Intravenous Thrombolysis in Chronic Intracranial Hemorrhage: A Five-Year Multicenter Study. Journal of Stroke and Cerebrovascular Diseases, 27, 620-624.
https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.09.037
